Anti-Human CD279 (PD-1) (Nivolumab)

Pricing & Details

Product No.LT1200
Clone
5C4.B8
Protein
PD-1
Formats AvailableView All
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
PD1; PD-1; CD279; SLEB2; hPD-1; hPD-l; hSLE1
Isotype
Human IgG1κ
Applications
B
,
FA
,
FC
,
IHC
Prod No.
Size
Price
Avail.
Qty
Add to cart
LT1200-Custom
Custom
In stock
Max:
Min: 1
Step: 1
LT1200-1 mg
1.0 mg
$175.00
In stock
Max:
Min: 1
Step: 1
LT1200-5 mg
5.0 mg
$650.00
In stock
Max:
Min: 1
Step: 1
LT1200-25 mg
25 mg
$2,450.00
In stock
Max:
Min: 1
Step: 1
LT1200-50 mg
50 mg
$3,750.00
In stock
Max:
Min: 1
Step: 1
LT1200-100 mg
100 mg
$5,100.00
In stock
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Human/Cynomolgus Monkey
Host Species
Human
Expression Host
HEK-293
FC Effector Activity
Active
Immunogen
Human PD-1
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
Formulation
This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Nivolumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
IHC
FA
FC
B
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Nivolumab. Clone 5C4.B8 binds to the extracellular portion of Human/Cynomolgus PD-1 and does not bind to other IgG superfamily proteins. This product is for research use only.
Antigen Distribution
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Background
Programmed cell death protein 1 (PD-1) is a protein on the surface of cells that plays a role in the maintenance of self-tolerance. PD-1 promotes self-tolerance via the down-regulation of the immune system which results in the suppression of T cell inflammatory activity. PD-L1 and PD-L2 are the two ligands known to bind PD-1. PD-L1 has increased expression in several cancers.1 PD-L2 has a more limited expression and is primarily expressed by dendritic cells and only some tumor lines. Inhibition of the interaction of PD-1 with its ligands can function as an immune checkpoint blockade through the improvement of In vitro T-cell responses and via the mediation of anti-tumor activity.2 Nivolumab disrupts the negative signal that is responsible for T-cell activation and proliferation by binding to PD-1 on activated immune cells to selectively block the interaction of the PD-1 receptor with its ligands.3 Emerging research suggests that combined blockade of PD-1 and CTLA-4, with nivolumab and ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.4 This cost-effective, research-grade Anti-Human CD279 (PD-1) (Nivolumab) utilizes the same variable regions from the therapeutic antibody Nivolumab making it ideal for research projects.

Antigen Details

Protein
Ligand/Receptor
PD-L1 and PD-L2
PubMed
NCBI Gene Bank ID
Research Area
Costimulatory Molecules
.
Immuno-Oncology
.
Immunology

References & Citations

1. Minato, N. et al. (2002) Proc Natl Acad Sci U S A. 99(19): 12293–97.
2. Korman, AJ. et al. (2014) Cancer Immunol Res. 2(9):846-56.
3. Li, Y. et al. (2016) MAbs. 8(5):951-60.
4. Wolchok, JD. et al. (2013) N Engl J Med 369(2):122-33.
Flow Cytometry
IHC

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.